Talks on finding a buyer for all or part of the Organon pharmaceuticals operations in Oss have failed, owner Merck said in a statement on Wednesday.

Over 2,000 jobs are set to go because Merck is planning to shut down one production line and move the R&D department to the US.
Three names had circulated in the press as possible buyers: Takeda Pharmaceuticals of Japan, African pharma group Aspen and Dutch biotech firm Pantarhei Bioscience.
‘This is very disappointing and difficult for us,’ board chairman Joep Pluymen said in the statement. The company now plans to look at ‘internal opportunities’ to keep some jobs.
According to the Volkskrant, the works council, supervisory board and unions are unhappy at the company’s ‘one-sided’ decision to break off the takeover talks and are planning to go to court.
They want the court to force the company to press on with looking for alternatives.